TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
+3.64%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.91B
AUM Growth
+$2.91B
(+2.1%)
Cap. Flow
+$60.2M
Cap. Flow
% of AUM
2.07%
Top 10 Holdings %
Top 10 Hldgs %
30.43%
Holding
226
New
26
Increased
31
Reduced
48
Closed
30
Top Buys
| 1 |
Elevance Health
ELV
|
$45.8M |
| 2 |
Abbott
ABT
|
$37.5M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$31.8M |
| 4 |
Moderna
MRNA
|
$29.3M |
| 5 |
Gilead Sciences
GILD
|
$26.5M |
Top Sells
| 1 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$59.8M |
| 2 |
Becton Dickinson
BDX
|
$21.5M |
| 3 |
Humana
HUM
|
$19.1M |
| 4 |
Bio-Techne
TECH
|
$16.8M |
| 5 |
NovoCure
NVCR
|
$15.2M |
Sector Composition
| 1 | Healthcare | 95.75% |
| 2 | Real Estate | 2.99% |
| 3 | Industrials | 0.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Replimune Group
REPL
$460M
| $6.68M | 0.23% |
+219,060
| New | +$6.68M |
|
102
Agilent Technologies
A
$35.5B
| $6.68M | 0.23% |
52,525
| – | – |
|
103
Apellis Pharmaceuticals
APLS
$3.51B
| $6.55M | 0.23% |
152,538
-63,479
| -29% | -$2.72M |
|
|
VRNA
104
Verona Pharma
VRNA
$9.18B
| $6.29M | 0.22% |
751,905
| – | – |
|
105
Amicus Therapeutics
FOLD
$2.42B
| $6.14M | 0.21% |
621,659
+216,033
| +53% | +$2.13M |
|
106
Y-mAbs Therapeutics
YMAB
$390M
| $5.98M | 0.21% |
197,820
+121,272
| +158% | +$3.67M |
|
107
Arvinas
ARVN
$580M
| $5.68M | 0.2% |
85,997
+12,538
| +17% | +$829K |
|
|
TRIL
108
DELISTED
Trillium Therapeutics Inc.
TRIL
| $5.68M | 0.2% |
529,226
-288,558
| -35% | -$3.1M |
|
|
MORF
109
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $5.67M | 0.19% |
+89,559
| New | +$5.67M |
|
|
BCEL
110
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
| $5.4M | 0.19% |
352,424
| – | – |
|
111
Teladoc Health
TDOC
$1.37B
| $5.39M | 0.19% |
29,664
-26,856
| -48% | -$4.88M |
|
112
Align Technology
ALGN
$9.59B
| $5.38M | 0.18% |
9,925
-116
| -1% | -$62.8K |
|
113
Travere Therapeutics
TVTX
$1.75B
| $5.32M | 0.18% |
+212,869
| New | +$5.32M |
|
|
TCRR
114
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $5.21M | 0.18% |
+235,808
| New | +$5.21M |
|
115
Aurinia Pharmaceuticals
AUPH
$1.58B
| $5.17M | 0.18% |
397,920
+97,309
| +32% | +$1.26M |
|
|
AMED
116
DELISTED
Amedisys
AMED
| $5.14M | 0.18% |
19,395
| – | – |
|
117
Zai Lab
ZLAB
$3.48B
| $5.01M | 0.17% |
37,523
| – | – |
|
118
Healthpeak Properties
DOC
$12.3B
| $4.77M | 0.16% |
150,392
| – | – |
|
119
Revvity
RVTY
$9.68B
| $4.76M | 0.16% |
37,094
| – | – |
|
120
Cogent Biosciences
COGT
$1.83B
| $4.72M | 0.16% |
537,742
| – | – |
|
121
Icon
ICLR
$14B
| $4.63M | 0.16% |
+23,592
| New | +$4.63M |
|
122
BridgeBio Pharma
BBIO
$9.91B
| $4.6M | 0.16% |
+74,714
| New | +$4.6M |
|
123
Personalis
PSNL
$430M
| $4.42M | 0.15% |
+179,731
| New | +$4.42M |
|
124
Centene
CNC
$14.8B
| $4.3M | 0.15% |
67,290
-16,855
| -20% | -$1.08M |
|
125
Intellia Therapeutics
NTLA
$1.26B
| $4.27M | 0.15% |
+53,180
| New | +$4.27M |
|